Can Natural Products Exert Neuroprotection without Crossing the Blood–Brain Barrier?
Open Access
- 25 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3356
Abstract
The scope of evidence on the neuroprotective impact of natural products has been greatly extended in recent years. However, a key question that remains to be answered is whether natural products act directly on targets located in the central nervous system (CNS), or whether they act indirectly through other mechanisms in the periphery. While molecules utilized for brain diseases are typically bestowed with a capacity to cross the blood–brain barrier, it has been recently uncovered that peripheral metabolism impacts brain functions, including cognition. The gut–microbiota–brain axis is receiving increasing attention as another indirect pathway for orally administered compounds to act on the CNS. In this review, we will briefly explore these possibilities focusing on two classes of natural products: omega-3 polyunsaturated fatty acids (n-3 PUFAs) from marine sources and polyphenols from plants. The former will be used as an example of a natural product with relatively high brain bioavailability but with tightly regulated transport and metabolism, and the latter as an example of natural compounds with low brain bioavailability, yet with a growing amount of preclinical and clinical evidence of efficacy. In conclusion, it is proposed that bioavailability data should be sought early in the development of natural products to help identifying relevant mechanisms and potential impact on prevalent CNS disorders, such as Alzheimer’s disease.Keywords
Funding Information
- Nature et technologies (2021-PR-281704)
- Santé (253895)
This publication has 235 references indexed in Scilit:
- A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer diseaseJournal of Clinical Investigation, 2012
- Do polyphenols enter the brain and does it matter? Some theoretical and practical considerationsGenes & Nutrition, 2011
- Obesity, diabetes, and risk of Parkinson's diseaseMovement Disorders, 2011
- Decreased Clearance of CNS β-Amyloid in Alzheimer’s DiseaseScience, 2010
- Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer DiseaseJAMA, 2010
- Metabolic fate of polyphenols in the human superorganismProceedings of the National Academy of Sciences, 2010
- Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related DisordersBiological Psychiatry, 2010
- Multivariate and Univariate Analysis of Continuous Arterial Spin Labeling Perfusion MRI in Alzheimer's DiseaseJournal of Cerebral Blood Flow & Metabolism, 2007
- Clearance of amyloid-β by circulating lipoprotein receptorsNature Medicine, 2007
- Docosahexaenoic acid alters bilayer elastic propertiesProceedings of the National Academy of Sciences, 2007